Clinical practice guidelines for the management of atopic dermatitis 2018.
atopic dermatitis
clinical practice guidelines
clinical questions
evidence-based medicine
treatment
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
19
08
2019
accepted:
21
08
2019
pubmed:
11
10
2019
medline:
14
4
2020
entrez:
11
10
2019
Statut:
ppublish
Résumé
Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
Identifiants
pubmed: 31599013
doi: 10.1111/1346-8138.15090
doi:
Substances chimiques
Dermatologic Agents
0
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
1053-1101Subventions
Organisme : Ministry of Health, Labour and Welfare
Informations de copyright
© 2019 Japanese Dermatological Association.
Références
Kawashima M, Takigawa M, Nakagawa H et al. Guidelines for management of atopic dermatitis. Jpn J Dermatol 2000; 110: 1099-1104.
Furue M, Furukawa F, Hide M, Takehara K, Japanese Dermatological Association. Guidelines for therapy for atopic dermatitis 2003. Jpn J Dermatol 2003; 113: 451-457.
Furue M, Furukawa F, Hide M, Takehara K. Japanese Dermatological Association Guidelines for therapy of atopic dermatitis 2004. Jpn J Dermatol 2004; 114: 135-142.
Furue M, Saeki H, Furukawa F et al. Guidelines for therapy of atopic dermatitis. Jpn J Dermatol 2008; 118: 325-342.
Furue M, Saeki H, Furukawa F et al. Guidelines for therapy of atopic dermatitis. Jpn J Dermatol 2009; 119: 1515-1534.
Katoh N, Saeki H, Nakahara T et al. Guidelines for therapy of atopic dermatitis 2016. Jpn J Dermatol 2016; 126: 121-155.
Kohno Y, Yamamoto S, The study group for Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of atopic dermatitis 1999. (In Japanese.)
Furue M, Yamamoto S, The study group for Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of atopic dermatitis 2001. (In Japanese.)
Kohno Y, Yamamoto S, The study group for Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of atopic dermatitis 2005. (In Japanese).
Kohno Y, Yamamoto S, The study group for Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of atopic dermatitis 2006. (In Japanese).
Katayama I, Kohno Y, Japanese Society of Allergology. Japanese Guideline for Atopic Dermatitis 2009. Tokyo: Kyowa Kikaku, 2009. (In Japanese).
Katayama I, Kohno Y, Japanese Society of Allergology. Japanese Guideline for Atopic Dermatitis 2012. Tokyo: Kyowa Kikaku, 2012. (In Japanese).
Katayama I, Kohno Y, Japanese Society of Allergology. Japanese Guideline for Atopic Dermatitis 2015. Tokyo: Kyowa Kikaku, 2015. (In Japanese).
Committee for Nasal Allergy Guidelines. Nasal Allergy Guidelines 2016. Tokyo: Life Science, 2016. (In Japanese).
Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatol 2005; 125: 183-200.
Melnik B, Hollmann J, Plewig G. Decreased stratum corneum ceramides in atopic individuals-a pathobiochemical factor in xerosis? Br J Dermatol 1988; 119(4): 547-549.
Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol 2016; 42: 1-8.
Kono M, Nomura T, Ohguchi Y et al. Comprehensive screening for a complete set of Japanese-population-specific filaggrin gene mutations. Allergy 2014; 69: 537-540.
De Benedetto A, Rafaels NM, McGirt LY et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011; 127: 773-786.
Tokumasu R, Yamaga K, Yamazaki Y et al. Dose-dependent role of claudin-1 in vivo inorchestrating features of atopic dermatitis. Proc Natl Acad Sci U S A 2016; 113(28): E4061-E4068.
Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR21 + lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 2000; 115: 640-646.
Nakamura K. TARC (thymus and activation regulated chemokine). Jpn J Clin Med 2010; 68: 41-45. (In Japanese).
Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. Human Langerhans cells induce distinct IL-22-producing CD4 + T cells lacking IL-17 production. Proc Natl Acad Sci U S A 2009; 106: 21795-21800.
Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity 2015; 43: 29-40.
Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopicdermatitis: therapeutic implications. J Dermatol 2014; 41: 205-212.
Murota H, Izumi M, Abd El-Latif MI. Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis. J Allergy Clin Immunol 2012; 130: 671-682.
Ikoma A, Fartasch M, Heyer G et al. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology 2004; 27: 212-217.
Murota H, Katayama I. Evolving understanding on the aetiology of thermally provoked itch. Eur J Pain 2016; 20: 47-50.
Parsad D, Saini R. The sound of scratching: an unusual cause of neurotic excoriations. Dermatology 1997; 195: 74.
Schut C, Grossman S, Gieler U, Kupfer J, Yosipovitch G. Contagious itch: what we know and what we would like to know. Front Hum Neurosci 2015; 9: 57.
Lavery MJ, Stull C, Kinney MO, Yosipovitch G. Nocturnal pruritus: the battle for a peaceful night's sleep. Int J Mol Sci 2016; 17: 425.
Gotoh Y, Omori Y, Andoh T, Kuraishi Y. Tonic inhibition of allergic itch signaling by the descending noradrenergic system in mice. J Pharmacol Sci 2011; 115: 417-420.
Hirota T, Takahashi A, Kubo M et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet 2012; 44: 1222-1226.
Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1991; 165: 1-53.
Williams H, Robertson C, Stewart A et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103: 125-138.
Williams H, Stewart A, von Mutius E et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol 2008; 121: 947-954.
Morita E. Analysis of Prevalence and Identification of Causative and Exacerbation Factors of Atopic Dermatitis and Studies for Improvement of Living Environment to Prevent the Development and Exacerbation of Symptoms. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Part, Vol. 2. Japanese)(In: 2002:; 184-186.
Yamamoto S. [Identification of Causative and Exacerbation Factors of Atopic Dermatitis and Studies for Improvement of Living Environment to Prevent the Development and Exacerbation of Symptoms. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Part 1, 2003: 71-77]. (In Japanese).
Saeki H, Iizuka H, Mori Y et al. Prevalence of atopic dermatitis in Japanese elementary schoolchildren. Br J Dermatol 2005; 152: 110-114.
Saeki H, Oiso N, Honma M et al. Prevalence of atopic dermatitis in Japanese adults and community validation of the U.K. diagnostic criteria. J Dermatol Sci 2009; 55: 140-141.
Ueda H. Epidemiology of atopic dermatitis. Jpn J Ped Med 2000; 32: 986-992. (In Japanese).
Mikawa H. Epidemiological Research of atopic dermatitis. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. 1995: 247-251. (In Japanese).
Ohta K, Oka N, Okazaki K et al. Prevalecen of atopic dermatitis in elementary schoolsin western Japan-Comparison between 1992 and 2002. Jpn J Pediatr Allergy Clin Immunol 2003; 17: 255-268. (In Japanese).
Kusunoki T, Morimoto T, Nishikomori R et al. Changing prevalence and severity of childhood allergic diseases in Kyoto, Japan, from 1996 to 2006. Allergol Int 2009; 58: 543-548.
Ricci G, Patrizi A, Baldi E et al. Long-term followup of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol 2006; 55: 765-771.
Illi S, von Mutius E, Lau S et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004; 113: 925-931.
Sandström MH, Faergemann J. Prognosis and prognostic factors in adult patients with atopic dermatitis: a long-term follow-up questionnaire study. Br J Dermatol 2004; 150: 103-110.
Kohno Y. Identification of Causative and Exacerbation Factors of Atopic Dermatitis and Studies for Improvement of Living Environment to Prevent the Development and Exacerbation of Symptoms. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. 2009: 1-11. (In Japanese).
Fukiwake N, Furusyo N, Kubo N et al. Incidence of atopic dermatitis in nursery school children -a follow-up study from 2001 to 2004, Kyushu University Ishigaki Atopic Dermatitis Study (KIDS). Eur J Dermatol 2006; 16: 416-419.
Ohshima Y, Yamada A, Hiraoka M et al. Early sensitization to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermatitis: results of a 4-year followup study. Ann Allergy Asthma Immunol 2002; 89: 265-270.
Anan S, Yamamoto N. Natural remission of atopic dermatitis. Skin Res 1996; 38(Suppl. 18): 13-16. (In Japanese).
Wakamori T, Katoh N, Hirano S et al. Atopic dermatitis, dry skin and serum IgE in children in a community in Japan. Int Arch Allergy Immunol 2009; 149: 103-110.
Katoh N, Hirano S, Kishimoto S. Prognostic factor of adult patients with atopic dermatitis. J Dermatol 2008; 35: 477-483.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm-Venereol (Stockh) 1980; 92(Suppl): 44-47.
Williams HC, Burney PGJ, Pembroke AC, Hay RJ. The UK Working Party's Diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131: 406-416.
Aoki T, Fukuzumi J, Adachi J et al. Re-evaluation of skin lesion distribution in atopic dermatitis. Acta Derm Venereol (Stockh) 1992; 176(Suppl): 19-23.
Hsu AP, Davis J, Puck JM, Holland SM, Freeman AF. Autosomal Dominant Hyper IgE Syndrome. http://www.ncbi.nlm.nih.gov/books/NBK25507/
Aoki T. The second report from the Advisory Committee for Atopic Dermatitis Severity Classification. Jpn J Dermatol 2001; 111: 2023-2033. (In Japanese).
Yoshida H. Interim report from the Advisory Committee for Atopic Dermatitis Severity Classification. Jpn J Dermatol 1998; 108: 1491-1496. (In Japanese.).
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on atopic dermatitis. Dermatology 1993; 186: 23-31.
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
Eichenfield LF, Tom WL, Berger TG et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71: 116-132.
Yamada H, Noda T, Matsukura M, Sugihara K, Yudate T, Tezuka T. Evaluation of itching by visual analogue scale (VAS). Skin Res 1996; 38(Suppl 18): 71-77. (In Japanese with English abstract.).
Kido-Nakahara M, Katoh N, Saeki H et al. Comparative cut-off value setting of pruritus intensity in visual analogue scale and verbal rating scale. Acta Derm Venereol 2015; 95: 345-346.
Furue M, Ebata T, Ikoma A et al. Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. Acta Derm Venereol 2013; 93: 214-215.
Phan NQ, Blome C, Fritz F et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-507.
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004; 140: 1513-1519.
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.
Gaunt DM, Metcalfe C, Ridd M. The Patient-Oriented Eczema Measure in young children: responsiveness and minimal clinically important difference. Allergy 2016; 71: 1620-1625.
Stalder JF, Barbarot S, Wollenberg A et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011; 66: 1114-1121.
Takahashi N, Suzukamo Y, Nakamura M et al. Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes 2006; 4: 46.
Fukuhara S, Suzukamo Y. Japanese version of DLQI and Skindex-29. Allergy Pract 2007; 358: 23-27. (In Japanese).
Higaki Y, Kawamoto K, Kamo T, Horikawa N, Kawashima M, Chren MM. The Japanese version of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Dermatol 2002; 29: 693-698.
Ohya Y, Sasaki R, Matsumoto M et al. Development of Japanese Version of Children's Dermatology Life Quality Index (CDLQI). Jap J Allergol 2002; 51: 265. (In Japanese).
Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-949.
Kondo-Endo K, Ohashi Y, Nakagawa H et al. Development and validation of a questionnaire measuring quality of life in primary caregivers of children with atopic dermatitis (QPCAD). Br J Dermatol 2009; 161: 617-625.
Katsunuma T, Tan A, Ohya Y. Short verstion of quality of life questionnaire in primarycaregivers of children with atopic dermatitis (QPCAD): development and validation of QP9. Jap J Allergol 2013; 62: 33-46. (In Japanese with English abstract.).
Chamlin SL, Cella D, Frieden IJ et al. Development of the Childhood Atopic Dermatitis Impact Scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J Invest Dermatol 2005; 125: 1106-1111.
Yamaguchi C, Futamura M, Chamlin SL, Ohya Y, Asano M. Development of a Japanese Culturally Modified Version of the Childhood Atopic Dermatitis Impact Scale (JCMV-CADIS). Allergol Int 2016; 65: 312-319.
Smith PH, Ownby DR. Clinical significance of immunoglobulin E. In: Adkinson NF Jr, Bochner BS, Burks AW et al., eds. Middleton's Allergy, Principles and Practice. Philadelphia: Mosby, 2014; 1108-1119.
Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci 2006; 43: 75-84.
Tamaki K, Saeki H, Kadono T et al. Serum TARC/CCL17 levels as a disease marker of atopic dermatitis. Jpn J Dermatol 2006; 116: 27-39. (In Japanese with English abstract.).
Fujisawa T, Nagao M, Noma Y et al. Clinical Utility serum TARC/CCL17 for monitoring clinical couse of atopic dermatitis in children. Jpn J Pediatr Allergy Clin Immunol 2005; 19: 744-757. (In Japanese with English abstract.).
Kataoka Y. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol 2014; 41: 221-229.
Fujisawa T, Nagao M, Hiraguchi Y et al. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis. Pediatr Allergy Immunol 2009; 20: 633-641.
Nagao M, Inagaki S, Kawano T et al. SCCA2 is a reliable biomarker for evaluating pediatric atopic dermatitis. J Allergy Clin Immunol 2018; 141: 1934-1936.e11.
Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroid potency. Pediatr Dermatol 1996; 13: 239-245.
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1-191.
Eichenfield LF, Tom WL, Berger TG et al. Guideline of care for the management of atopic dermatitis. Section2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71: 116-132.
https://www.nice.org.uk/guidance/ta81/chapter/Appendix-D-Topical-corticosteroids-for-the-treatment-of-atopic-eczema-grouped-by-potency
Long CC, Finlay AY. The finger-tip unit-a new practical measure. Clin Exp Dermatol 1991; 16: 444-447.
Long CC, Finlay AY, Averill RW. The rule of hand: 4hand area = 2 FTU = 1 g. Arch Dermatol 1992; 128: 1129-1130.
Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005; 152: 130-141.
Green C, Colquitt JL, Kirby J, Davidson P, Payne E. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 1-120.
Feldman RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invst Dermatol 1967; 48: 181-183.
Hajar T, Lesham YA, Hanifin JM et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol 2015; 72: 541-549.
Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol 2014; 133: 1615-1625.
Schmitt J, von Kobyletzki L, Svensson Å, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164: 415-428.
Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000; 105: 794-799.
Schlessinger J, Miller B, Gilbert RD, Plott RT, Vanos Study Group. An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. Arch Dermatol 2006; 142: 1568-1572.
Friedlander SF, Hebert AA, Allen DB, Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002; 46: 387-393.
Hebert AA, Friedlander SF, Allen DB. Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr 2006; 149: 378-382.
Hirano S, Katoh N, Yasuno H. A retrospective analysis of the severity of atopic dermatitis. Jpn J Dermatol 1995; 105: 1309-1315. (In Japanese with English abstract.).
Nakagawa N, Tsukahara Y, Tetsumoto K. Statistical analysis of clinical risk factors associated with atopic cataract occurrence. J Eye 2000; 17: 1679-1684. (in Japanese).
Furue M, Kawashima M, Furukawa F et al. Clinical epidemiology: a prospective questionnaire study for atopic dermatitis patients (part 2). Jpn J Clin Dermatol 2001; 65: 83-92. (in Japanese).
Arikawa J, Higaki Y, Takamura E, Kawashima M. A study of intraocular pressure in patients with atopic Dermatitis and topical steroid treatment on the face. Jpn J Dermatol 2002; 112: 1107-1110. (In Japanese with English abstract.).
Work group of guidelines of care for the management of atopic dermatitis Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71: 116-132.
Singh S, Gupta A, Pandey SS, Singh G. Tachyphylaxis to histamine-induced wheal suppression by topical 0.05% clobetasol propionate in normal versus croton oil-induced dermatitis skin. Dermatology 1996; 193: 121-123.
Singh G, Singh PK. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int J Dermatol 1966; 25: 324-326.
Japanese FK 506 Ointment Study Group. Clinical guidance for treatment of patients with atopic dermatitis by tacrolimus ointment 0.1% and 0.03%. Jpn J Clin Dermatol 2003; 57: 1217-1234. (In Japanese with English abstract).
Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-816.
Schneeweiss S, Doherty M, Zhu S et al. Topical treatments with pimecrolimus, tacrolimus and medium-to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009; 219: 7-21.
Ohtsuki M, Shiragasawa C, So M, Nakagawa H. The long-term safety and effectiveness of 0.03% Tacrolimus ointment in the treatment of pediatric patients with atopic dermatitis-interim report of long-term special drug use -results survey. J Pediatr Dermatol 2013; 32: 127-137. (In Japanese with English abstract).
Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26: 1176-1193.
Caproni M, Torchia D, Antiga E et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. Br J Dermatol 2007; 156: 312-319.
Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004; 114: 887-895.
Yanai K, Yoshikawa T, Yanai A et al. The clinical pharmacology of non-sedating antihistamines. Pharmacol Ther 2017; 178: 148-156.
Yanai K, Zhang D, Tashiro M et al. Positron emission tomography evaluation of sedative properties of antihistamines. Expert Opin Drug Saf 2011; 10: 613-622.
Yanai K, Tashiro M, Okamura N et al. Non-sedating second-generation antihistamines: the penetration through blood-brain barrier by PET. Nishinihon J Dermatol 2009; 71: 3-6. (In Japanese.).
Okamura N, Yanai K, Higuchi M et al. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 2000; 129: 115-123.
McDonald K, Trick L, Boyle J et al. Sedation and antihistamines: an update. Review of inter-drug difference using proportional impairment ratios. Hum Psychopharmacol 2008; 23: 555-570.
Kawashima M, Furue M, Hide M et al. A comparative study of antipruritic effects and the occurrence of drowsiness between sedating and non-sedating antihistamines (ACROSS trial). J Clin Therap Med 2011; 27: 563-573. (In Japanese).
Hiraoka K, Tashiro M, Grobosch T et al. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opin Drug Saf 2015; 14: 199-206.
Dillon SR, Sprecher C, Hammond A et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752-760.
Yamamura K, Uruno T, Fukui Y et al. The transcription factor EPAS1 links DOCK8 deficiency to atopic skin inflammation via IL-31 induction. Nat Commun 2017; 8: 13946.
Ruzicka T, Hanifin JM, Kabashima K et al. Anti-Interleukin-31 Receptor antibody for atopic dermatitis. N Engl J Med 2017; 376: 826-835.
Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol 2014; 41: 205-212.
Toyoda M, Nakamura M, Morohashi M et al. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002; 147: 71-79.
Pincelli C, Fantini F, Giannetti A et al. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol 1990 Jun; 122: 745-750.
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21: 606-619.
Study Group of NeoralⓇ Treatment for Atopic Dermatitis. Treatment: Safety and efficacy of intermittent cyclosporin MEPC therapy in patients with severe adult atopic dermatitis: multicenter, openlabel, long-term clinical trial. Jpn J Clin Dermatol 2009; 63: 163-171. (in Japanese).
Hashizume H, Ito T, Yagi H et al. Efficacy and safety of preprandial versus postprandial administration of lowdose cyclosporin microemulsion (Neoral)in patients with psoriasis vulgaris. J Dermatol 2007; 34: 430-434.
Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San)for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Int Arch Allergy Immunol 2011; 155: 141-148.
Kobayashi H, Ishii M, Takeuchi S et al. Efficacy and safety of a traditional herbal medicine, Hochu-ekki-to in the long-term management of Kikyo (delicate constitution)patients with atopic dermatitis: a 6-month, multicenter, double-blind, randomized, placebo-controlled study. Evid Based Complement Alternat Med 2010; 7: 367-373.
Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 1992; 126: 179-184.
Sheehan MP, Rustin MHA, Atherton DJ et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992; 340: 13-17.
Fung AY, Look PC, Chong LY, But PP, Wong E. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int J Dermatol 1999; 38: 387-392.
Japanese Society for Pediatric Allergy and Clinical Immunogy. Japanese pediatric guideline for food allergy 2016. Tokyo: Kyowa Kikaku, 2016. (In Japanese).
Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014; 70(401): pp. e1-14; quiz 15.
Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol 2014; 70: 417. e1-10; quiz 27.
Chi CC, Kirtschig G, Aberer W et al. Evidence-based (S3)guideline on topical corticosteroids in pregnancy. Br J Dermatol 2011; 165: 943-952.
Loden M, Andersson AC, Andersson C et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol 2002; 82: 45-47.
Kawashima M, Numano K, Ishizaki C. Usefulness of moisturizers for dermato-physiological dysfunction in patients with atopic dermatitis. Jpn J Dermatol 2007; 117: 969-977. (In Japanese with English abstract.).
van Zuuren EJ, Fedorowicz Z, Christensen R et al. Emollients andmoisturisers for eczema (Review). Cochrane Database Sys Rev 2016; 2: CD012119.
Simpson EL, Chalmers JR, Hanifin JM et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014; 134: 818-823.
Horimukai K, Morita K, Narita M et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 2014; 134: 824-830.
Ohatani M, Ohtani M, Nozawa A et al. A study of the influence of the volume and frequency of application on the efficacy of moisturizers. Jpn J Dermatol 2012; 122: 39-43. (In Japanese).
Nakamura M, Uemura K, Nemoto O, Miyachi Y. Evaluation of an optimal method for topical application of moisturizer. Skin Res 2006; 5: 311-316. (In Japanese with English Abstract).
Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985; 65: 102-105.
Kawashima M, Hayashi N, Nogita T, Yanagisawa K, Mizuno A. The usefulness of moisturizers for maintenance of remission in atopic dermatitis. Jpn J Dermatol 2007; 117: 1139-1145. (In Japanese with English abstract.).
Murota H, Izumi M, Abd El-Latif MI et al. Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis. J Allergy Clin Immunol 2012; 130: 671-682.
Denda M, Sokabe T, Fukumi-Tominaga T, Tominaga M. Effects of skin surface temperature on epidermal permeability barrier homeostasis. J Invest Dermatol 2007; 127: 654-659.
Cheng X, Jin J, Hu L et al. TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. Cell 2010; 141: 331-343.
Uehara M, Takada K. Use of soap in the management of atopic dermatitis. Clin Exp Dermatol 1985; 10: 419-425.
Uehara M. Use of soap in bathing for atopic dermatitis. Rinsho Derma (Tokyo) 1981; 23: 1049-1052. (In Japanese).
Nicolaides N. Skin lipids. IV: Biochemistry and function. J Am Oil Chem Soc 1965; 42: 708-712.
Fonacier LS, Aquino MR. The role of contact allergy in atopic dermatitis. Immunol Allergy Clin North Am 2010; 30: 337-350.
Giordano-Labadie F, Rance F, Pellegrin F, Bazex J, Dutau G, Schwarze HP. Frequency of contact allergy in children with atopic dermatitis: results of a prospective study of 137 cases. Contact Dermatitis 1999; 40: 192-195.
Tamagawa-Mineoka R, Masuda K, Ueda S et al. Contact sensitivity in patients with recalcitrant atopic dermatitis. J Dermatol 2015; 42: 720-722.
Takayama K, Yokozaki H, Matsunaga K et al. The guidelines for the management of contact dermatitis. Jpn J Dermatol 2009; 119: 1757-1793. (in Japanese).
Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. Cochrane Database Syst Rev 2008; (1): CD005203.
Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Cochrane Database Syst Rev 2012; (19): Cd000133.
Schafer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 1999; 104: 1280-1284.
Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. I. Normal sweat gland function. J Am Acad Dermatol 1989; 20: 537-563.
Watabe A, Sugawara T, Kikuchi K, Yamasaki K, Sakai S, Aiba S. Sweat constitutes several natural moisturizing factors, lactate, urea, sodium, and potassium. J Dermatol Sci 2013; 72: 177-182.
Yokozeki H, Hibino T, Takemura T, Sato K. Cysteine proteinase inhibitor in eccrine sweat is derived from sweat gland. Am J Physiol 1991; 260: R314-R320.
Komatsu N, Takata M, Otsuki N et al. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 2003; 121: 542-549.
Eissa A, Amodeo V, Smith CR, Diamandis EP. Kallikrein-related peptidase-8 (KLK8)is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem 2011; 286: 687-706.
Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002; 119: 1090-1095.
López-García B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 2005; 125: 108-115.
Schittek B, Hipfel R, Sauer B et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2001; 2: 1133-1137.
Imayama S, Shimozono Y, Hoashi M et al. Reduced secretion of IgA to skin surface of patients with atopic dermatitis. J Allergy Clin Immunol 1994; 94: 195-200.
Hiragun T, Ishii K, Hiragun M et al. Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. J Allergy Clin Immunol 2013; 132: 608-615.
Griffin T, Sulzberger MB. Miliaria and anhidrosis. J Invest Dermatol 1967; 49: 379-385.
Shiohara T, Doi T, Hayakawa J. Defective sweating responses in atopic dermatitis. Curr Probl Dermatol 2011; 41: 68-79.
Papa C, Kligman A. Mechanism of eccrine anhidrosis. J Invest Dermatol 1966; 47: 1-9.
Eishi K, Lee JB, Bae SJ, Takenaka M, Katayama I. Impaired sweating function in adult atopic dermatitis: results of the quantitative sudomotor axon reflex test. Br J Dermatol 2002; 147: 683-688.
Kijima A, Murota H, Matsui S et al. Abnormal axon reflex-mediated sweating correlates with high state of anxiety in atopic dermatitis. Allergol Int 2012; 61: 469-473.
Takahashi A, Murota H, Matsui S et al. Decreased sudomotor function is involved in the formation of atopic eczema in the cubital fossa. Allergol Int 2013; 62: 473-478.
Matsui S, Murota H et al. Dynamic analysis of histamine-mediated attenuation of acethylcholine-iduced sweating via GSK3b activation. J Invest Dermatol 2013; 134: 326-334.
Matsui S, Murota H, Ono E, Kikuta J, Ishii M, Katayama I. Olopatadine hydrochloride restores histamine-induced impaired sweating. J Dermatol Sci 2014; 74: 260-261.
Murota H, Matsui S, Ono E, Kijima A et al. Sweat, the driving force behind the normal skin: an emerging perspective on functional biology and regulatory mechanisms. J Dermatol Sci 2015; 77: 3-10.
Kong HH, Oh J, Deming C et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012; 22: 850-859.
Kobayashi T, Glatz M, Horiuchi K et al. Dysbiosis and staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity 2015; 42: 756-766.
Bath-Hextall FJ, Birnie AJ, Ravenscroft JC et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane revies. Br J Dermatol 2010; 163: 12-26.
Savolainen J, Lammintausta K, Kalimo K, Viander M. Candida albicans and atopic dermatitis. Clin Exp Allergy 1993; 23: 332-339.
Takechi M. Minimum effective dosage in the treatment of chronic atopic dermatitis with itraconazole. J Int Med Res 2005; 33: 273-283.
Mayser P, Kupfer J, Nemetz D et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream-results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006; 19: 153-158.
Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol 1995; 63: 624-635.
Steven J, Cowdell F, Latter S et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev 2014; (1): CD004054.
Lack G, Fox D, Northstone K et al. Factors associated with the development of peanut allergy in childhood. N Engl J Med 2003; 348: 977-985.
Lack G. Epidemiologic risks for food allergy. J Allergy Clin Immunol 2008; 122: 984-991.
Tsakok T, Marrs T, Mohsin M et al. Does atopic dermatitis cause food allergy? A systematic review J Allergy Clin Immunol 2016; 137: 1071-1078.
Natsume O, Kabashima S, Ohya Y. Two-step Egg Introduction for preventing egg allergy in High-risk Infants with eczema (PETIT study): a double-blind, placebo-controlled, parallel-group randomized clinical trial. Lancet 2017; 389: 276-286.
Fukuie T, Ohya Y, Ebisawa M et al. Proposal for prevention of hen's egg allergy. Japanese Society for Pediatric Allergy and Clinical Immunology. (June 16, 2017.). (In Japanese)
Ohta K, Oka N, Okazaki K et al. Prevalecen of atopic dermatitis in elementary schoolsin western Japan-Comparison between 1992 and 2002. Jpn J Pediatr Allergy Clin Immunol 2003; 17: 255-268. (In Japanese).
Iikura Y, Odasima Y, Kitabayashi T et al. Relationship between cedar pollen and some allergic symptoms. Allergol Immunol 2002; 9: 343-349. (In Japanese).
Werfel T, Heratizadeh A, Niebuhr M et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 2015; 136: 96-103.
Sidbury R, Davis DM, Cohen DE et al. Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71: 327-349.
Morita A. Phototherapy by using new wave lengths -narrow-band UVB, UVA1, 308 nm excimer blue light. In: Tamaki K, liduka H, Shimizu H, Tomita Y, Miyachi Y, Hashimoto K, Furue M, eds. Comprehensive Handbook of Clinical Dermatology 2008-2009. Tokyo: Nakayama Shoten, 2008; 55-64. (In Japanese)
Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo (chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 2014; 170: 501-513.
Morita A, Etoh T, Torii H, et al. Guidelines for phototerapy in psoriasis. Jpn J Dermatol 2016; 126: 1239-1262. (In Japanese).
Mukai H, Fukuda H, Suzuki T, Saotome A, Hayade E. Usefulness of inpatient care for atopic dermatitis: a questionnaire survey in patients with a history of hospitalization. Skin Res 2012; 11(Suppl 18): 43-47. (In Japanese with English Abstract).
Kataoka Y. Consideration of quality Index in clinical practice of atopic dermatitis. J Visual Dermatol 2014; 13: 1094-1097. (In Japanese).
Staab D, Diepgen TL, Fartasch M et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933-938.
Moore EJ, Williams A, Manias E, Varigos G, Donath S. Eczema workshops reduce severity of childhood atopic eczema. Australas J Dermatol 2009; 50: 100-106.
Futamura M, Masuko I, Hayashi K, Ohya Y, Ito K. Effects of a short-term parental education program on childhood atopic dermatitis: a randomized controlled trial. Pediatr Dermatol 2013; 30: 438-443.
Armstrong AW, Kim RH, Idriss NZ, Larsen LN, Lio PA. Online video improves clinical outcomes in adults with atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011; 64: 502-507.
Ersser SJ, Cowdell F, Latter S et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev 2014; CD004054.
Department of Dermatology, Kyushu University. Standard therapy for atopic dermatitis. http://www.kyudai-derm.org/atopy_care/index.html.2010. (In Japanese)
Environmental Restoration and Conservation Agency. Handbook of pediatric atopic dermatitis Prevention for exacerbation of asthma. (In Japanese). https://www.erca.go.jp/yobou/pamphlet/form/00/archives_1028.html. 2009.
Sepp E, Julge K, Vasar M et al. Intestinal microflora of Estonian and Swedish infants. Acta Paediatr 1997; 86: 956-961.
Bjorksten B, Naaber P, Sepp E et al. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999; 29: 342-346.
Itoh H. Pediatric allerc diseases and probiotics. Jpn J Pediatr 2006; 59: 1511-1521. (In Japanese).
Panduru M, Panduru NM, Sălăvăstru CM et al. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015; 29: 232-242.
Kim SO, Ah YM, Yu YM et al. Effects of probiotics for the treatment of atopic dermatitits: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2014; 113: 217-226.
Cuello-Garcia CA, Fiocchi A, Pawankar R et al. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics. World Allergy Organ J 2016; 9: 10.
Chang YS, Trivedi MK, Jha A, Lin YF et al. Synbiotics for prevention and treatment of atopic dermatitis: a meta-analysis of randomized clinical trials. JAMA Pediatr 2016; 170: 236-242.
Hide M, Yamamura Y, Morita E, Kohro O, Yamamoto S. Alternative treatments for atopic dermatitis : classification of the treatments and a questionnaire study. Nishinihon J Dermatol 2000; 62: 83-88. (In Japanese with English Abstract).
Kojima R, Fujiwara T, Matsuda A et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol 2013; 30: 29-35.
Takehara K, Iiduka H, Itoh M et al. Survey of health damage caused by inadequate treatment for atopic dermatitis. Jap J Dermatol 2000; 110: 1095. (In Japanese).
Pfab F, Huss-Marp J, Gatti A et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema-a blinded, randomized, placebo-controlled, crossover trial. Allergy 2010; 65: 903-910.
Siebenwirth J, Luedtke R, Remy W, Rakoski J, Borelli S, Ring J. Effectiveness of a classical homeopathic treatment in atopic eczema. A randomised placebo-controlled double-blind clinical trial. Forsch Komplementmed 2006; 2009(16): 315-323.
World Health Organization. Adherence to long-term therapies-evidence for action, 2003; http://whqlibdoc.who.int/publications/2003/9241545992.pdf
Ascertaining barriers for compliance: policies for safe, effective and costeffective use of medicines in Europe. Final report of the ABC project, 2012; Available at: http://www.ABCproject.eu
Ou HT, Feldman SR, Balkrishnan R. Understanding and improving treatment adherence in pediatric patients. Semin Cutan Med Surg 2010; 29: 137-140.
Masuko I. Introduction, Japanese Society of Pediatric Intractble Asthma and Allergic Diseases: Pediatric Allergy Educator Text. Practice Part. Tokyo: Shindan To Chiryo Sha Inc, 2013; 1-24. (In Japanese)